{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:48:31Z","timestamp":1791856111396,"version":"4.3.4"},"reference-count":17,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Fam Plann Reprod Health Care"],"accepted":{"date-parts":[[2014,5,20]]},"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1136\/jfprhc-2014-100980","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T10:04:10Z","timestamp":1402999450000},"page":"165-169","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Jaydess<sup>\u00ae<\/sup> levonorgestrel intrauterine system"],"prefix":"10.1136","volume":"40","author":[{"given":"Louise","family":"Melvin","sequence":"first","affiliation":[{"name":"Director, Faculty of Sexual & Reproductive Healthcare (FSRH) Clinical Effectiveness Unit, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Scott","sequence":"additional","affiliation":[{"name":"Researcher, FSRH Clinical Effectiveness Unit, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Craik","sequence":"additional","affiliation":[{"name":"Researcher, FSRH Clinical Effectiveness Unit, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"key":"2025090510293242000_40.3.165.1","unstructured":"Faculty of Sexual & Reproductive Healthcare Clinical Effectiveness Unit. Intrauterine Contraception . 2007. http:\/\/www.fsrh.org\/admin\/uploads\/CEUGuidanceIntrauterineContraceptionNov07.pdf [accessed 30 April 2014]."},{"key":"2025090510293242000_40.3.165.2","unstructured":"Bayer Healthcare. Formulary template. Jaydess 13.5 mg intrauterine delivery system (levonorgestrel). Contraception for up to 3 years. London, UK: Bayer Healthcare, 2014."},{"key":"2025090510293242000_40.3.165.3","unstructured":"Bayer plc. Summary of Product Characteristics: Jaydess 13.5 mg intrauterine delivery system. 2014. http:\/\/www.medicines.org.uk\/emc\/medicine\/28672\/SPC\/Jaydess+13.5+mg+intrauterine+delivery+system\/ [accessed 30 April 2014]."},{"key":"2025090510293242000_40.3.165.4","unstructured":"Bayer plc. Summary of Product Characteristics: Mirena. 2008. http:\/\/www.medicines.org.uk\/EMC\/medicine\/1829\/SPC\/Mirena\/ [accessed 30 April 2014]."},{"key":"2025090510293242000_40.3.165.5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.contraception.2012.01.015","article-title":"Quantative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system","volume":"86","author":"Seeber","year":"2012","journal-title":"Contraception"},{"key":"2025090510293242000_40.3.165.6","unstructured":"Bayer Healthcare. Highlights of Prescribing Information: Skyla. 2014. http:\/\/labeling.bayerhealthcare.com\/html\/products\/pi\/Skyla_PI.pdf [accessed 30 April 2014]."},{"key":"2025090510293242000_40.3.165.7","unstructured":"Faculty of Sexual & Reproductive Healthcare Clinical Effectiveness Unit. New Product Review: Jaydess\u00ae Levonorgestrel Intrauterine System (LNG-IUS) . 2014. http:\/\/www.fsrh.org\/pdfs\/CEUProductReviewJaydess.pdf [accessed 13 May 2014]."},{"key":"2025090510293242000_40.3.165.8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.fertnstert.2011.12.003","article-title":"A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena","volume":"97","author":"Gemzell-Danielsson","year":"2012","journal-title":"Fertil Steril"},{"key":"2025090510293242000_40.3.165.9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/AOG.0000000000000019","article-title":"Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial","volume":"122","author":"Nelson","year":"2013","journal-title":"Obstet Gynecol"},{"key":"2025090510293242000_40.3.165.10","doi-asserted-by":"crossref","unstructured":"Apter D Gemzell-Danielsson K Hauck B . Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril. Epub ahead of print: 10 April 2014. doi:10.1016\/j.fertnstert.2014.03.004.","DOI":"10.1016\/j.fertnstert.2014.03.004"},{"key":"2025090510293242000_40.3.165.11","unstructured":"National Institute for Health and Clinical Excellence (NICE). Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-acting Reversible Contraception . 2005. http:\/\/www.nice.org.uk\/pdf\/CG030fullguideline.pdf [accessed 30 April 2014]."},{"key":"2025090510293242000_40.3.165.12","unstructured":"Faculty of Sexual & Reproductive Healthcare Clinical Effectiveness Unit. Faculty Statement: New Inserter for Mirena\u00ae IUS . 2012. http:\/\/www.fsrh.org\/pdfs\/CEUstatementNewMirenaInserter.pdf [accessed 30 April 2014]."},{"key":"2025090510293242000_40.3.165.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2003.07.021"},{"key":"2025090510293242000_40.3.165.14","unstructured":"Faculty of Sexual & Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2009) . 2009. http:\/\/www.fsrh.org\/pdfs\/UKMEC2009.pdf [accessed 30 April 2014]."},{"key":"2025090510293242000_40.3.165.15","unstructured":"Joint Formulary Committee. British National Formulary. British National Formulary (BNF 65) . London, UK: British Medical Association and Royal Pharmaceutical Society, 2013."},{"key":"2025090510293242000_40.3.165.16","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.contraception.2013.10.019","article-title":"Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception","volume":"89","author":"Trussell","year":"2014","journal-title":"Contraception"},{"key":"2025090510293242000_40.3.165.17","unstructured":"Mithra Pharmaceuticals. Summary of Product Characteristics: Tresovelle. 2014. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1390198538525.pdf [accessed 30 April 2014]."}],"container-title":["Journal of Family Planning and Reproductive Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jfprhc-2014-100980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:49:14Z","timestamp":1757094554000},"score":1,"resource":{"primary":{"URL":"https:\/\/jfprhc.bmj.com\/lookup\/doi\/10.1136\/jfprhc-2014-100980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,6,17]]},"published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1136\/jfprhc-2014-100980"],"URL":"https:\/\/doi.org\/10.1136\/jfprhc-2014-100980","relation":{},"ISSN":["1471-1893","2045-2098"],"issn-type":[{"value":"1471-1893","type":"print"},{"value":"2045-2098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,17]]}}}